We develop innovative bioabsorbable
soft tissue support scaffolds for use in breast surgery.
Our GalaFLEX® scaffolds strengthen and stabilize tissue in breast
surgery with a predictable resorption rate for lasting reinforcement.
About Us
About Galatea Surgical, Inc.
Galatea Surgical, Inc. is passionate about bringing your patient’s Strength and Beauty to life through reinforcement of weak and compromised tissue with an innovative solution for soft tissue support. As a wholly owned subsidiary of Tepha, Inc., the Galatea team has created a portfolio of optimized soft tissue support devices utilizing a non-cadaveric, non-human, non-animal, non-synthetic, biologically derived fully absorbable material: poly-4-hydroxybutyrate (P4HB™) that delivers on the belief that real strength starts from within.
Galatea Vision
To forever change the standard of care in plastic and reconstructive surgery procedures, enriching patients’ lives.
Galatea Mission
To become the standard soft tissue support solution for both plastic and reconstructive surgeon and patients. To collaborate with scientists, engineers, surgeons, and patients to identify opportunities for innovative scientific approaches supported by evidence-based medicine that meet and exceed core surgeon and patient needs.
Galatea Surgical is proud to be a wholly owned subsidiary of Tepha, Inc.
About Tepha, Inc.
Tepha Inc., founded in 1998 and headquartered in Lexington, MA, is a supplier of medical devices focused on its proprietary P4HB polymer technology. Tepha’s products are designed and developed to elevate, support and reinforce and stimulate a tissue healing and regenerative processes. Commercial scaffolds and suture products based on Tepha’s absorbable P4HB polymer technology are currently utilized in general, orthopedic and plastic and reconstructive surgery.
As of 2020 there have been 29 regulatory clearances for products made from P4HB, including the Galatea collection of biologically derived scaffolds. To date, over 3 million patients have been implanted with P4HB devices worldwide, and over 60 clinical and scientific papers have been published.
Tepha Mission Statement
At Tepha, our vision has always been a simple one – to be the leader in tissue engineering and regenerative medicine. We advance surgeons’ ability to make structural repairs to the human body with unrivaled biomaterials that become much like the tissue that surrounds them; products that can be tailored to meet multiple applications across the spectrum of surgical repairs.
Go to
Galatea Brand History
The story begins in ancient Greece with Pygmalion, the mythical King of Cyprus. Unable to find true love, the young king dedicated his life to the arts and sculpture. Using his mastery of the arts, he carved a statue from ivory of the most perfect woman he could imagine. He was so taken with the beauty that he had created, he fell in love and named the statue Galatea.
He would gently kiss the statue each day to show his love. His adoration attracted the attention of the Goddess Aphro- dite who brought the sculpture to life. Pygmalion and Galatea lived their true love for the rest of their days. At Galatea Surgical, we share Galatea’s dedication to creating enduring examples of strength and beauty. Partnering with the surgical community, we strive to create examples of beauty and strength that stand the test of time.
He would gently kiss the statue each day to show his love. His adoration attracted the attention of the Goddess Aphro- dite who brought the sculpture to life. Pygmalion and Galatea lived their true love for the rest of their days. At Galatea Surgical, we share Galatea’s dedication to creating enduring examples of strength and beauty. Partnering with the surgical community, we strive to create examples of beauty and strength that stand the test of time.
History of P4HB™ Biopolymer
Researchers at MIT developed a recombinant system to produce Polyhydroxyalkanoates (PHAs) in microorganisms.
Researchers at Metabolix further developed recombinant systems for the industrial production of PHAs. In 1998, Tepha, Inc. was incorporated to pursue the medical applications of PHAs.
The first P4HB medical devices: TephaFLEX® Suture & Mesh received FDA clearance
Tepha partnered with B.Braun Medical who received the CE Mark for the P4HB device: MonoMax® Suture. MonoMax Suture was the first commercial launch of a P4HB device in Europe and in the US.
TephaFLEX® Mesh received FDA clearance for soft tissue reinforcement in Plastic Surgery and was first used for Plastic Surgery. Tepha partnered with Tornier® and commercially launched: BioFiber™ for Soft Tissue Reinforcement in the US.
Tepha partnered with Bard/Davol® to commercially launch the P4HB device: Phasix™ mesh for Hernia Repair in the US.
Galatea Surgical, Inc. became a wholly owned subsidiary of Tepha, Inc. to focus on plastic and reconstructive surgery.
Galatea Surgical, Inc. became a wholly owned subsidiary of Tepha, Inc. to focus on plastic and reconstructive surgery.
Tepha P4HB devices achieved milestone of treating
1 million patients globally, with over 1,000 aesthetic plastic surgery patients.
Galatea Surgical received CE Mark for use of GalaFLEX scaffold in breast surgery.
1 million patients globally, with over 1,000 aesthetic plastic surgery patients.
Galatea Surgical received CE Mark for use of GalaFLEX scaffold in breast surgery.
Galatea Surgical received FDA Clearance for the first and only 3-Dimensional scaffolds designed for plastic and reconstructive surgery.
Global expansion of the Galatea scaffold product portfolio.
CE approval of GalaFLEX 3D and GalaFLEX 3DR.
CE approval of GalaFLEX 3D and GalaFLEX 3DR.
Over 29 regulatory clearances on P4HB products and over 60 published clinical and scientific papers on P4HB
More than 3 million patients worldwide have been implanted with P4HB devices.
More than 3 million patients worldwide have been implanted with P4HB devices.
We develop innovative bioabsorbable soft tissue support scaffolds for use in breast surgery.
Our GalaFLEX® scaffolds strengthen and stabilize tissue in breast surgery with a predictable resorption rate for lasting reinforcement.
About Us
About Galatea Surgical, Inc.
Galatea Surgical, Inc. is passionate about bringing your patient’s Strength and Beauty to life through reinforcement of weak and compromised tissue with an innovative solution for soft tissue support. As a wholly owned subsidiary of Tepha, Inc., the Galatea team has created a portfolio of optimized soft tissue support devices utilizing a non-cadaveric, non-human, non-animal, non-synthetic, biologically derived fully absorbable material: poly-4-hydroxybutyrate (P4HB™) that delivers on the belief that real strength starts from within.
Galatea Vision
To forever change the standard of care in plastic and reconstructive surgery procedures, enriching patients’ lives.
Galatea Mission
To become the standard soft tissue support solution for both plastic and reconstructive surgeon and patients. To collaborate with scientists, engineers, surgeons, and patients to identify opportunities for innovative scientific approaches supported by evidence-based medicine that meet and exceed core surgeon and patient needs.
Galatea Surgical is proud to be a wholly owned subsidiary of Tepha, Inc.
About Tepha, Inc.
Tepha Inc., founded in 1998 and headquartered in Lexington, MA, is a supplier of medical devices focused on its proprietary P4HB polymer technology. Tepha's products are designed and developed to elevate, support and reinforce and stimulate a tissue healing and regenerative processes. Commercial scaffolds and suture products based on Tepha's absorbable P4HB polymer technology are currently utilized in general, orthopedic and plastic and reconstructive surgery.
As of 2019 there have been 29 regulatory clearances for products made from P4HB, including the Galatea collection of biologically derived scaffolds. To date, over 3 million patients have been implanted with P4HB devices worldwide, and over 60 clinical and scientific papers have been published.
As of 2019 there have been 29 regulatory clearances for products made from P4HB, including the Galatea collection of biologically derived scaffolds. To date, over 3 million patients have been implanted with P4HB devices worldwide, and over 60 clinical and scientific papers have been published.
Tepha Mission Statement
At Tepha, our vision has always been a simple one – to be the leader in tissue engineering and regenerative medicine. We advance surgeons' ability to make structural repairs to the human body with unrivaled biomaterials that become much like the tissue that surrounds them; products that can be tailored to meet multiple applications across the spectrum of surgical repairs.
Go to
Galatea Brand History
The story begins in ancient Greece with Pygmalion, the mythical King of Cyprus. Unable to find true love, the young king dedicated his life to the arts and sculpture. Using his mastery of the arts, he carved a statue from ivory of the most perfect woman he could imagine. He was so taken with the beauty that he had created, he fell in love and named the statue Galatea.
He would gently kiss the statue each day to show his love. His adoration attracted the attention of the Goddess Aphro- dite who brought the sculpture to life. Pygmalion and Galatea lived their true love for the rest of their days. At Galatea Surgical, we share Galatea’s dedication to creating enduring examples of strength and beauty. Partnering with the surgical community, we strive to create examples of beauty and strength that stand the test of time.
He would gently kiss the statue each day to show his love. His adoration attracted the attention of the Goddess Aphro- dite who brought the sculpture to life. Pygmalion and Galatea lived their true love for the rest of their days. At Galatea Surgical, we share Galatea’s dedication to creating enduring examples of strength and beauty. Partnering with the surgical community, we strive to create examples of beauty and strength that stand the test of time.
History of P4HB™
Biopolymer
1980s
Researchers at MIT developed a recombinant system to produce Polyhydroxyalkanoates (PHAs) in microorganisms.
1990s
Researchers at Metabolix further developed recombinant systems for the industrial production of PHAs. In 1998, Tepha, Inc. was incorporated to pursue the medical applications of PHAs.
2007 / 2008
The first P4HB medical devices: TephaFLEX® Suture & Mesh received FDA clearance
2009 / 2010
Tepha partnered with B.Braun Medical who received the CE Mark for the P4HB device: MonoMax® Suture. MonoMax Suture was the first commercial launch of a P4HB device in Europe and in the US.
2011
TephaFLEX® Mesh received FDA clearance for soft tissue reinforcement in Plastic Surgery and was first used for Plastic Surgery. Tepha partnered with Tornier® and commercially launched: BioFiber™ for Soft Tissue Reinforcement in the US.
2012 / 2013
Tepha partnered with Bard/Davol® to commercially launch the P4HB device: Phasix™ mesh for Hernia Repair in the US.
Galatea Surgical, Inc. became a wholly owned subsidiary of Tepha, Inc. to focus on plastic and reconstructive surgery.
Galatea Surgical, Inc. became a wholly owned subsidiary of Tepha, Inc. to focus on plastic and reconstructive surgery.
2014/2015
Tepha P4HB devices achieved milestone of treating
1 million patients globally, with over 1,000 aesthetic plastic surgery patients.
Galatea Surgical received CE Mark for use of GalaFLEX® scaffold in breast surgery.
1 million patients globally, with over 1,000 aesthetic plastic surgery patients.
Galatea Surgical received CE Mark for use of GalaFLEX® scaffold in breast surgery.
2016
Galatea Surgical received FDA Clearance for the first and only 3-Dimensional scaffolds designed for plastic and reconstructive surgery.
2019
Global expansion of the Galatea scaffold product portfolio.
CE approval of GalaFLEX 3D and GalaFLEX 3DR.
CE approval of GalaFLEX 3D and GalaFLEX 3DR.
2020
Over 29 regulatory clearances on P4HB products and over 60 published clinical and scientific papers on P4HB.
More than 3 million patients worldwide have been implanted with P4HB devices
More than 3 million patients worldwide have been implanted with P4HB devices
